Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease

NCT05660746 is registered in ClinicalTrials.gov with Children's Hospital Medical Center, Cincinnati as lead sponsor.

NCT NCT05660746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's Disease
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Phase
Phase 2/3
Overall status
Recruiting
Start date
July 1, 2023
Completion date
March 31, 2027
Enrollment
180 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease